Protective Antigen Inhibitors
1 drugsAbout Protective Antigen
Protective Antigen (PA) is a key protein of anthrax toxin, mediating toxin entry into host cells. Its function in anthrax pathogenesis makes it a crucial target for therapeutic intervention.
PA is targeted to combat anthrax infections, though there is currently no genetic evidence directly linking it to specific diseases.
RAXIBACUMAB is the only FDA-approved drug targeting PA, developed by HUMAN GENOME SCIENCES INC. It is an antibody and the sole drug in the 'other' therapeutic area category.
Top Protective Antigen Drugs
HUMAN GENOME SCIENCES INC. is the only company with an approved drug targeting Protective Antigen.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
Protective Antigen Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Protective Antigen, using antibody modality.
Exploring alternative modalities like small molecules could offer a competitive advantage.
Protective Antigen Clinical Trials 3 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Protective Antigen. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Protective Antigen Drug Approval Timeline (2012 - 2012)
The first and only drug, RAXIBACUMAB, was approved in 2012.
The lack of recent approvals suggests market saturation or challenges in developing new PA-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Protective Antigen. A trial counts if an approved drug acting on Protective Antigen is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.